LRP1 and COVID-19: COVID-19 patients display a heterogenous disease course. Novel biomarkers are needed for the early prediction of the disease course to tailor therapy for COVID-19. Since LRP1 has anti-inflammatory effects, we study the sLRP1 levels in hospitalized patients with COVID-19.